Jan. 7, 2013
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care, today announced that the Company ended 2012 with a cash balance of approximately
and expects 2013 net cash burn to be between
$45 and $50 million
. The Company also announced it secured a
term loan from Oxford Finance and Silicon Valley Bank.
"2013 will be a pivotal year, with the potential approval and launch of our first partnered program, which is expected to drive the Company to be cash flow positive as early as 2014," said Gregory I. Frost, Ph.D., President and Chief Executive Officer. "Based on these near-term growth drivers and our strong cash position, Halozyme is well financed to advance our pipeline and support launches of proprietary products."
term loan was fully drawn at close on
December 28, 2012
and has a maturity date of
, 2016. The proceeds will be used for working capital and other near-term growth initiatives. Additional details of the new credit facility are outlined in the Company's Current Report on Form 8-K dated
January 4, 2013
filed with the Securities and Exchange Commission.
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex
recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer,
, ViroPharma and Intrexon. Halozyme is headquartered in
San Diego, CA.
For more information on how we are innovating, please visit our corporate website at